Published in PLoS One on October 05, 2011
Scalable molecular dynamics with NAMD. J Comput Chem (2005) 59.49
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (2001) 36.00
Development and testing of a general amber force field. J Comput Chem (2004) 23.29
DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res (2010) 13.68
Improved protein-ligand docking using GOLD. Proteins (2003) 7.94
Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev (2006) 7.92
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer (2006) 5.58
A modified version of the Cornell et al. force field with improved sugar pucker phases and helical repeat. J Biomol Struct Dyn (1999) 5.14
Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem (1995) 3.52
Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov (2007) 3.36
Matrix metalloproteinases and angiogenesis. J Cell Mol Med (2005) 2.89
Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci (2006) 2.81
Nonlinear scaling schemes for Lennard-Jones interactions in free energy calculations. J Chem Phys (2007) 1.94
Tautomerism in computer-aided drug design. J Recept Signal Transduct Res (2003) 1.70
Zinc-binding groups modulate selective inhibition of MMPs. ChemMedChem (2008) 1.47
The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res (2006) 1.40
The 1.8-A crystal structure of a matrix metalloproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition. J Biol Chem (2001) 1.17
Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. J Mol Biol (2007) 1.13
Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors. Curr Pharm Des (2007) 1.08
Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor. Biochim Biophys Acta (2002) 1.01
Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug Discov Today (2007) 0.98
Inhibition of matrix metalloproteinase-2 by PARP inhibitors. Biochem Biophys Res Commun (2009) 0.95
Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis. Rheumatology (Oxford) (2001) 0.95
Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett (2001) 0.89
Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg Med Chem Lett (2005) 0.86
Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol (1998) 0.86
Screening of matrix metalloproteinases available from the protein data bank: insights into biological functions, domain organization, and zinc binding groups. J Chem Inf Model (2007) 0.85
Molecular dynamics simulations of the active matrix metalloproteinase-2: positioning of the N-terminal fragment and binding of a small peptide substrate. Proteins (2008) 0.85
Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase. J Med Chem (2011) 0.82
Analysis of X-ray structures of matrix metalloproteinases via chaotic map clustering. BMC Bioinformatics (2010) 0.81
N-substituted homopiperazine barbiturates as gelatinase inhibitors. Bioorg Med Chem (2011) 0.80
Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship. Bioorg Med Chem Lett (2009) 0.80
Inhibition of monoamine oxidase-B by condensed pyridazines and pyrimidines: effects of lipophilicity and structure-activity relationships. J Med Chem (1998) 0.78
Thermal fluctuations of grafted microtubules provide evidence of a length-dependent persistence length. Proc Natl Acad Sci U S A (2006) 2.41
Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J Biol Chem (2006) 2.05
Expedient solid-phase synthesis of fluorogenic protease substrates using the 7-amino-4-carbamoylmethylcoumarin (ACC) fluorophore. J Org Chem (2002) 1.26
Elastic properties of proteins: insight on the folding process and evolutionary selection of native structures. J Mol Biol (2002) 1.13
Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands. J Biol Chem (2007) 1.07
Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility. J Clin Invest (2002) 1.05
Conformations of confined biopolymers. Phys Rev E Stat Nonlin Soft Matter Phys (2007) 1.04
Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes. J Med Chem (2002) 1.03
Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem (2007) 1.03
Molecular switch for CLC-K Cl- channel block/activation: optimal pharmacophoric requirements towards high-affinity ligands. Proc Natl Acad Sci U S A (2008) 1.02
Design, synthesis and biological evaluation of indane-2-arylhydrazinylmethylene-1,3-diones and indol-2-aryldiazenylmethylene-3-ones as beta-amyloid aggregation inhibitors. Eur J Med Chem (2009) 0.96
9,10-Anthraquinone hinders beta-aggregation: how does a small molecule interfere with Abeta-peptide amyloid fibrillation? Protein Sci (2009) 0.94
Potent galloyl-based selective modulators targeting multidrug resistance associated protein 1 and P-glycoprotein. J Med Chem (2011) 0.94
Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. J Med Chem (2004) 0.92
Impact of species-dependent differences on screening, design, and development of MAO B inhibitors. J Med Chem (2006) 0.92
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities. Eur J Med Chem (2010) 0.89
Attenuation of autoimmune disease in Fas-deficient mice by treatment with a cytotoxic benzodiazepine. Arthritis Rheum (2003) 0.89
CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity. Electrophoresis (2009) 0.88
Improving quantitative structure-activity relationships through multiobjective optimization. J Chem Inf Model (2009) 0.88
Inactivation of the glutamine/amino acid transporter ASCT2 by 1,2,3-dithiazoles: proteoliposomes as a tool to gain insights in the molecular mechanism of action and of antitumor activity. Toxicol Appl Pharmacol (2012) 0.88
G protein inactive and active forms investigated by simulation methods. Proteins (2009) 0.88
CERAPP: Collaborative Estrogen Receptor Activity Prediction Project. Environ Health Perspect (2016) 0.87
Mechanism of action of cyclophilin a explored by metadynamics simulations. PLoS Comput Biol (2009) 0.86
Carbamate prodrug concept for hydroxamate HDAC inhibitors. ChemMedChem (2011) 0.86
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity. J Med Chem (2005) 0.85
Screening of matrix metalloproteinases available from the protein data bank: insights into biological functions, domain organization, and zinc binding groups. J Chem Inf Model (2007) 0.85
Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors. Bioorg Med Chem (2013) 0.85
Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption. ChemMedChem (2011) 0.84
QSAR and QSPR studies of a highly structured physicochemical domain. J Chem Inf Model (2006) 0.83
In-vivo administration of CLC-K kidney chloride channels inhibitors increases water diuresis in rats: a new drug target for hypertension? J Hypertens (2012) 0.83
Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase. J Med Chem (2011) 0.82
1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor. Bioorg Med Chem (2008) 0.81
Three-dimensional microtubule behavior in Xenopus egg extracts reveals four dynamic states and state-dependent elastic properties. Biophys J (2008) 0.81
Analysis of X-ray structures of matrix metalloproteinases via chaotic map clustering. BMC Bioinformatics (2010) 0.81
Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine-resistant cancer cells. Mol Cancer Ther (2005) 0.81
A chemocentric approach to the identification of cancer targets. PLoS One (2012) 0.81
Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening. Bioorg Med Chem (2005) 0.81
Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonists. Bioorg Med Chem (2012) 0.81
Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase. Bioorg Med Chem (2012) 0.81
Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists. Eur J Med Chem (2013) 0.81
An integrated approach to ligand- and structure-based drug design: development and application to a series of serine protease inhibitors. J Chem Inf Model (2008) 0.80
Probing the S1' site for the identification of non-zinc-binding MMP-2 inhibitors. ChemMedChem (2013) 0.80
Coumarin, chromone, and 4(3H)-pyrimidinone novel bicyclic and tricyclic derivatives as antiplatelet agents: synthesis, biological evaluation, and comparative molecular field analysis. Bioorg Med Chem (2003) 0.80
Structural insight into peroxisome proliferator-activated receptor gamma binding of two ureidofibrate-like enantiomers by molecular dynamics, cofactor interaction analysis, and site-directed mutagenesis. J Med Chem (2010) 0.80
Multiphoton absorption of myoglobin-nitric oxide complex: relaxation by D-NEMD of a stationary state. J Phys Chem B (2012) 0.79
New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones. J Med Chem (2002) 0.79
Neuronal nicotinic acetylcholine receptor agonists: pharmacophores, evolutionary QSAR and 3D-QSAR models. Curr Top Med Chem (2004) 0.79
Homo- and hetero-bivalent edrophonium-like ammonium salts as highly potent, dual binding site AChE inhibitors. Bioorg Med Chem (2008) 0.79
Integration of QSAR models for bioconcentration suitable for REACH. Sci Total Environ (2013) 0.79
A k-NN algorithm for predicting the oral sub-chronic toxicity in the rat. ALTEX (2014) 0.79
Strategies of multi-objective optimization in drug discovery and development. Expert Opin Drug Discov (2011) 0.79
Kidney CLC-K chloride channels inhibitors: structure-based studies and efficacy in hypertension and associated CLC-K polymorphisms. J Hypertens (2016) 0.78
First selective dual inhibitors of tau phosphorylation and Beta-amyloid aggregation, two major pathogenic mechanisms in Alzheimer's disease. ACS Chem Neurosci (2014) 0.78
1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A2B adenosine receptor antagonists: design, synthesis, structure-affinity and structure-selectivity relationships. Bioorg Med Chem (2008) 0.78
Computational methods for the design of potent aromatase inhibitors. Expert Opin Drug Discov (2013) 0.78
Design, synthesis, and biological evaluation of coumarin derivatives tethered to an edrophonium-like fragment as highly potent and selective dual binding site acetylcholinesterase inhibitors. ChemMedChem (2010) 0.78
Computer-aided structure-based design of multitarget leads for Alzheimer's disease. J Chem Inf Model (2014) 0.78